|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Study Type: | Interventional |
|---|---|
| Study Design: | Open Label, Uncontrolled, Single Group Assignment |
| Conditions: |
Multiple Myeloma Stem Cell Transplantation |
| Interventions: |
Drug: Arsenic Trioxide Drug: Melphalan Drug: Ascorbic Acid |
Participant Flow
| Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations |
|---|
| Recruitment Period: 03/31/2004 through 08/02/2005. All pariticipants recruited at U.T. M.D. Anderson Cancer Center. |
| Significant events and approaches for the overall study following participant enrollment, but prior to group assignment |
|---|
| No text entered. |
| Description | |
|---|---|
| Arsenic Trioxide + Vitamin C + Melphalan | Arsenic Trioxide + Ascorbic Acid + Melphalan as a preparative regimen for autologous stem cell transplantation (delivered on Day 0) |
| Arsenic Trioxide + Vitamin C + Melphalan | |
|---|---|
| STARTED | 48 |
| COMPLETED | 48 |
| NOT COMPLETED | 0 |
More Information
| All Principal Investigators ARE employed by the organization sponsoring the study. |
| Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data |
|---|
| No text entered. |
| Responsible Party: | U.T. M.D. Anderson Cancer Center ( Muzaffar H. Qazilbash, MD/Associate Professor ) |
| Study ID Numbers: | 2003-0603 |
| Study First Received: | April 15, 2008 |
| Results First Received: | March 13, 2009 |
| Last Updated: | May 21, 2009 |
| ClinicalTrials.gov Identifier: | NCT00661544 History of Changes |
| Health Authority: | United States: Institutional Review Board |